Proteome-wide autoantibody screening and holistic autoantigenomic analysis

unveil COVID-19 signature of autoantibody landscape

Kazuki M Matsuda, MD, PhD,[1*] Yoshiaki Kawase, PhD,[2*] Kazuhiro Iwadoh, MD,

PhD,[1] Makoto Kurano, MD, PhD,[3] Yutaka Yatomi, MD, PhD,[4] Koh Okamoto, MD, MS,

PhD,[5] Kyoji Moriya, MD, PhD,[5,6] Hirohito Kotani,[1] MD, PhD,[1] Teruyoshi Hisamoto,

MD, PhD,[1] Ai Kuzumi, MD, PhD[1], Takemichi Fukasawa MD, PhD[1], Asako

Yoshizaki-Ogawa, MD, PhD[1], Masanori Kono, MD, PhD,[7] Tomohisa Okamura, MD,

PhD,[7] Hirofumi Shoda, MD, PhD,[7] Keishi Fujio, MD, PhD,[7] Kei Yamaguchi, PhD,[8]

Taishi Okumura,[8] Chihiro Ono,[9] Yuki Kobayashi, PhD,[8] Ayaka Sato,[8] Ayako Miya,[8]

PhD, Naoki Goshima, PhD,[8] Rikako Uchino,[9] Yumi Murakami, PhD,[9] Hiroshi

Matsunaka, PhD,[9] Hiroshi Imai, PhD,[2] Shinichi Sato, MD, PhD,[1] Rudy Raymond, PhD,

[2] Ayumi Yoshizaki, MD, PhD[1#]

1. Department of Dermatology, The University of Tokyo Graduate School of Medicine,

Tokyo, Japan

2. Department of Computer Science, The University of Tokyo Graduate School of

Information Science and Technology, Tokyo, Japan

3. Department of Clinical Laboratory Medicine, The University of Tokyo Graduate

School of Medicine, Tokyo, Japan

4. Graduate School, International University of Health and Welfare, Tokyo, Japan

5. Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan

6. Division of Infection Prevention and Control, Postgraduate School of Healthcare,

Tokyo Healthcare University, Tokyo, Japan

7. Department of Allergy and Rheumatology, The University of Tokyo Graduate

School of Medicine, Tokyo, Japan

8. ProteoBridge Corporation, Tokyo, Japan

9. NOV Academic Research, TOKIWA Pharmaceutical Co., Ltd., Tokyo, Japan

* Equally contributed.

 # Corresponding authors

Ayumi Yoshizaki, MD, PhD

Department of Dermatology and Department of Clinical Cannabinoid Research, The

University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo,

Japan, 1138655

Phone: +81-3-3815-5411

ORCID: 0000-0002-8194-9140

E-mail: ayuyoshi@me.com

Summary

This study presents "aUToAntiBody Comprehensive Database (UT-ABCD)", a

comprehensive catalog of autoantibody profiles in 284 human individuals. The subjects

include patients diagnosed with Coronavirus disease 2019 (COVID-19; n = 73),

systemic sclerosis (SSc; n = 32), systemic lupus erythematosus (SLE; n = 60),

anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV; n = 29), atopic

dermatitis (AD; n = 26), as well as healthy controls (HC; n = 64). Our investigation

employs proteome-wide autoantibody screening (PWAbS) that utilizes 13,352

autoantigens displayed on wet protein arrays (WPAs). Our WPAs display human

proteins synthesized *in vitro* utilizing a wheat germ cell-free system, maintained in a

hydrated state. Our findings demonstrated significant elevation in the number of IgG

autoantibody positivity in COVID-19, SSc, SLE, AAV, and AD patients compared to

HCs. Employing machine learning, we distinguished COVID-19 cases with high

accuracy based on autoantibody profiles, notably identifying antibodies against proteins

encoded by *BCORP1* and *KAT2A* as highly specific to COVID-19 (specificity: 87% and

97%, respectively). Our research highlights the effectiveness of integrating PWAbS and

autoantigenomics in exploring immune responses in COVID-19 and other diseases. It

provides a deeper understanding of the autoimmunity landscape in human disorders and

introduces a new bioresource for further investigation.

Introduction

Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),[1] has brought a global pandemic since early 2020 with threat on human health and public safety throughout the world.[2] The pathophysiology of COVID-19 is characterized by multiple organ injuries triggered by excessive immune response.[3,4] Cytokine storm in the lung causes acute respiratory distress syndrome, which leads to hypoxemia, respiratory failure, requirement of ventilation, and even death. One of the biggest challenges in clinical management of COVID-19 patients lies in accurately identifying and categorizing cases at higher risk of such serious clinical course. Known risk factors include older age, male gender, smoking, diabetes, obesity, hypertension, immunodeficiency, and malignancies.[5]

Humoral immunity plays pivotal roles in COVID-19. Although dramatic success of mRNA vaccines and SARS-CoV-2 neutralizing monoclonal antibodies in preventing serious illnesses, accumulating evidence have suggested the vicious roles of dysregulated humoral immunity.[6–10] As well as earlier work linking anti-cytokine antibodies to mycobacterial, staphylococcal and fungal diseases,[11,12] autoantibodies against cytokines have been described in COVID-19.[13] Especially, anti-type I Interferon

antibodies distinguished ~10% of life-threatening pneumonia and ~20% of deaths from

COVID-19.[6–8] A high-throughput screening by yeast display of the secretome further

revealed the presence of autoantibodies against several immune factors, including

chemokines.[14] In addition, autoantibodies characteristic of systemic autoimmune

disorders, such as anti-phospholipid antibodies, anti-nuclear antibodies and rheumatoid

factor, were reported in COVID-19.[15] More recently, association between COVID-19

severity and autoantibodies targeting G protein-coupled receptors and renin-angiotensin

system-related proteins has been reported.[16]

To comprehensively understand such clinical significance of autoantibodies in

human diseases including COVID-19, high-precision autoantibody measurement with a

proteome-wide scale is necessary. Herein, we employed an original protein microarray

technology, which includes over 13,350 proteins, for proteome-wide autoantibody

screening (PWAbS),[17–19] in the serum samples derived from individual patients. Our

pipeline integrates human cDNA library (HuPEX),[20] a wheat germ cell-free system for

high-throughput *in vitro* protein synthesis,[21–23] and technology for manipulating protein

arrays kept in moist conditions during the entire handling process,[24] namely wet protein

arrays (WPAs). We have applied this method in multiple inflammatory or malignant

disorders for validating its potential for illustrating the "autoantibody landscape" of

human disorders, which revealed its usefulness for holistic evaluation of disease-related

autoantibodies,[19] developing novel biomarkers,[17] and moreover, investigating unknown

pathophysiology driven by autoantibodies.[18] While the significant body of work that has

utilized proteome-wide approaches to investigate autoantibodies in the context of

COVID-19, [9,10] our study provides a complementary perspective by a focus on a

Japanese cohort, use of a different technology, comparison with a variety of conditions

other than COVID-19, and longitudinal analysis.

Our aim was to demonstrate the utility of our omics-based methodology for

autoantibody evaluation and data interpretation procedure, so-called "autoantigenomics,"

targeting COVID-19. In 2020, Moritz *et al.* defined autoantigenomics as a branch of

systems immunology, which holistically analyze the repertoire of autoantibodies

engaging omics-based bioinformatical approaches including hierachical cluster analysis,

enrichment analysis, and machine learning.[25] The concept of autoantigenomics stand on

hypotheses that there might be differences in the sets of targeted antigens underlying

intra-disease heterogeneity in human, which would be supported by our novel data

shown below.

Results

Overview

We recruited 73 patients with COVID-19, 32 patients with systemic sclerosis

(SSc), 60 patients with systemic lupus erythematosus (SLE), 29 patients with

anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), 26 patients with

atopic dermatitis (AD), and 64 healthy controls (HC) for serum sample collection

(**Extended Table 1**). For each individual serum, PWAbS was performed focusing on

IgG autoantibodies (**Fig. 1A**). Our WPA included 84.8% of previously reported

housekeeping genes (**Fig. 1B**).[26] Based on genes expressed at more than 3.5 transcripts

per million (TPM) in the Genotype-Tissue Expression (GTEx) V8,[27] our WPA covered

72.1% of expressed human genes (**Fig. 1C**).

The digest of the results is available as "aUToAntiBody Comprehensive

Database (UT-ABCD)" at http://www.ut-abcd.org. We found that sum of autoantibody

levels (SAL), defined as the sum of all quantified values for the 13,352 displayed

autoantigens, was significantly elevated in patients with COVID-19 (median

[interquartile range]: 4418 [3325-5392] AU), SSc (5784 [3960-7338] AU), or SLE

(5963 [4543-7386] AU), compared to HCs (3014 [2289-3851] AU), while there was no

statistically significant difference in SAL between AD (3664 [2419-5451] AU) or AAV

(3842 [3281-4547] AU) patients and HCs (Extended **Fig. 2A**). This tendency was

consistent across both gender and age groups. (**Extended Fig. 2B**).

Threshold Determination and Positivity Counts

To establish the threshold for determining serum positivity of each

autoantibody, Z-scores were calculated based on the mean and standard deviation

values among healthy controls (HCs). Analysis revealed that over 99% of Z-scores in

HCs were below 4 (**Extended Fig. 1C, 1D, and 1E**). Consequently, a threshold of

Z-scores > 4 was set to define autoantibody seropositivity. The number of positive

autoantibodies was then counted for each individual and compared across different

conditions (**Fig. 2A**). This analysis demonstrated a significant increase in the number of

autoantibodies in patients with COVID-19, AD, AAV, SLE, and SSc compared to HCs.

Identification of disease-specific autoantibodies

We identified distinct sets of autoantibodies that showed a more than twofold

significant increase in each disease condition relative to HCs (**Fig. 2B**). Notably, certain

autoantibodies were unique to each disease (**Fig. 2C**). To illustrate the variability in

serum levels of these disease-specific autoantibodies across individuals, we utilized

uniform manifold approximation and projection (UMAP). UMAP analysis

demonstrated inter- and intra-disease heterogeneity in autoantibody profiles. However,

the UMAP plots did not show clear clustering based on disease state, indicating

substantial overlap among the different conditions (**Fig. 2D**). Gene ontology analysis

linked to the genes responsible for the proteins targeted by such disease-specific

autoantibodies pointed to shared biological functions, with a focus on viral infection

pathways and cytokine signaling in immune system, in COVID-19, SLE, and AAV (**Fig.**

2E and 2F). Holistic analysis of autoantibodies targeting cytokines, or their receptors

displayed on our WPAs revealed that strong positivity for autoantibodies targeting type

1 interferon was specifically observed in COVID-19 patients, while weak positivity was

seen in SLE patients (**Extended Fig. 2**).

Selection of machine learning frameworks

To further investigate the association between autoantibody profiles and

COVID-19, we adopted a machine learning approach. We tested nine different methods

to differentiate COVID-19 cases from the others: simple linear regression, Ridge

regression, logistic regression with data normalization, logistic regression with data

standardization, support vector machine (SVM) with data normalization, SVM with

data standardization, and extremely gradient boosting decision trees (XGBoost). As a

result, XGBoost showed the highest value of the area under the receiver-operator

characteristics curve (ROC-AUC) and Matthew's Correlation Coefficient (MCC) for

distinction of COVID-19 cases from the others (**Extended Table 2**). Consequently, we

opted to focus on this method for our subsequent analysis.

Performance of XGBoost

In our subsequent analysis using the entire dataset, we experimented with

binary (COVID-19 vs. others), ternary (mild COVID-19 vs. moderate to severe

COVID-19 vs. others), and multiclass (mild COVID-19 vs. moderate to severe

COVID-19 vs. AAV vs. AD vs. SSc vs. SLE vs. HCs) classifications through XGBoost.

The models achieved high accuracy in both binary and ternary classifications and

showed significantly better outcomes than chance in the complex seven-class

classification (**Extended Table 3**). The most significant autoantibodies identified across

all models are depicted in **Fig. 3A, 3B, and 3C**, with autoantibodies against

translational products from *BCL6 Corepressor Pseudogene 1* (*BCORP1*) emerging as a

top feature in every model. Similarly, antibodies against K-Acetyltransferase 2A

(KAT2A) were consistently prominent. Notably, Anti-BCORP1 and anti-KAT2A Abs

were highlighted as important items in all the candidate machine learning methods

tested (**Extended Fig. 3**). There was a correlation between anti-BCORP Abs and

anti-KAT2A Abs as illustrated in **Fig. 3D, 3E, and 3F**. Remarkably, established serum

markers for SSc and SLE, such as anti-topoisomerase 1 (TOP1) Abs, anti-centromere

protein-B (CENPB) Abs, anti-tripartite motif-containing protein 21 (TRIM21) Abs,

anti-small nuclear ribonucleoprotein polypeptide (SNRP)-A Abs, and anti-SNRPB Abs,

were also identified. The visualization of mean serum levels of these prominent markers

through spider charts revealed distinctive patterns across the different conditions (**Fig.**

3G, 3H, and 3I). We also attempted to integrate clinical features, specifically sex and

age, into the classifiers. As a result, while age ranked second in the 3-class classification

task and in the fourth in the 7-class classification task (**Extended Fig. 4A, 4B, and 4C**) ,

it did not lead to improvement in overall performance across all classification tasks

(**Extended Table 3**).

Minimum feature model

We evaluated the effectiveness of key features identified by machine learning

algorithms for COVID-19 classification by training an XGBoost model during each

iteration of cross-validation, using the top 1 to 5 features highlighted in the previous

2-class classification task (**Extended Fig.5**). Our analysis showed that even a single

feature, BCORP1, achieves ROC-AUC exceeding 0.85, demonstrating strong

discriminative power. While incorporating additional features enhanced some

performance metrics, we observed a plateau beyond three features, suggesting that

minimal models can still achieve high clinical relevance.

To further validate these findings, we trained a logistic regression model using

the top two and top five features (**Extended Table 4**). Two-feature model (BCORP1

and KAT2A) achieved an AUC of 0.912, confirming that these markers are highly

informative for COVID-19 classification. Five-feature model (BCORP1, KAT2A,

RPS4X, BEGAIN, and TRIM21) improved accuracy, recall, precision, and F1-score.

However, the ROC-AUC remained like that of the two-feature model. These results

indicate that BCORP1 and KAT2A are key features for distinguishing COVID-19 cases,

and our machine-learning approach is effective in identifying important biomarkers.

Clinical relevance of autoantibodies

The serum levels of the top 20 autoantibodies highlighted through multi-class

classification through XGBoost for each participant were depicted in a heatmap (**Fig.**

4A). Hierarchical clustering identified three unique groups of autoantibodies: cluster I,

which included two autoantibodies highly specific to COVID-19 (anti-BCORP1 and

anti-KAT2A Abs); cluster II, comprising autoantibodies that are commonly elevated

across various conditions; and cluster III, involving well-established biomarkers for SSc

and SLE. Principal component analysis (PCA) effectively distinguished between seven

categories (**Fig. 4B**), particularly using principal component (PC) 2 as an indicator for

COVID-19 (**Fig. 4C**). Correspondingly, antibodies against BCORP1 and KAT2A

constituted the predominant contribution to PC2 (**Fig. 4D**).

To validate the PWAbS results using WPAs in COVID-19 patients, we

performed enzyme-linked immunosorbent assays (ELISA) to quantify serum levels of

anti-KAT2A antibodies, employing recombinant KAT2A produced in a Baculovirus

expression system. The analysis revealed a statistically significant positive correlation

between the results obtained from PWAbS and ELISA (**Extended Fig. 6A**). In contrast,

ELISA using recombinant BCL2 co-repressor (BCOR), which shares approximately

99% nucleotide sequence similarity with BCORP1 and was synthesized in HEK293

cells, showed no correlation with the serum levels of anti-BCORP1 antibodies measured

by WPAs (**Extended Fig. 6B**).

Serum levels of anti-BCORP1 were the highest in COVID-19 among the

examined conditions (**Fig. 4E**). This trend was consistent among both sex and age

groups (**Extended Fig. 6C**). When the cutoff value was set at the mean + 4SD in

healthy controls (HCs), only one individual in the HC group showed serum positivity

for BCORP1, compared to 61 patients with COVID-19 (P < 0.001, two-sided Fisher's

exact test). Receiver operating characteristic (ROC) curve analysis demonstrated a

sensitivity of 79% and a specificity of 87% (**Fig. 4F**). For anti-KAT2A antibodies,

serum levels were highest in COVID-19 patients across all age and sex groups (**Figure**

4G and Extended Fig. 6D). With the cutoff set at the mean + 4SD in HCs, only one

HC individual showed serum positivity for KAT2A, while 16 COVID-19 patients tested

positive (P = 0.0045, two-sided Fisher's exact test). ROC curve analysis indicated a

sensitivity of 15% and a specificity of 97% (**Fig. 4H**). We also explored the link

between COVID-19 clinical outcomes and the presence of anti-BCORP1 or

anti-KAT2A Abs, but no significant association was found (**Extended Table 5 and 6**).

Time course of autoantibody levels during COVID-19

Finally, we enhanced our analysis by including "late" time point samples. The

data presented thus far derive exclusively from "early" time points, defined as within 10

days of symptom onset. To conduct a longitudinal evaluation of the humoral immune

response, we incorporated paired serum samples from 41 individuals, including both

"early" time points and "late" time points, defined as 11–20 days after symptom onset.

These samples were used for PWAbS and for assessing IgG levels against

SARS-CoV-2 particles: the nucleocapsid protein (N), spike protein (S), and the receptor

binding domain (RBD) of S. Consistent with our prior findings, early timepoint samples

showed IgG against N, S, and RBD in only a small part of the patients, with a marked

increase in most patients by the late timepoint (**Fig. 5A**). To the contrary, SAL remained

unchanged over time (**Fig. 5B**). Further exploration revealed a significant decrease in

293 autoantibodies and increase in 116 autoantibodies over the course of the infection,

including those targeting BCORP1 and KAT2A (**Fig. 5C and 5D**). There was no

observed correlation between these autoantibodies and IgG levels against N, S, and

RBD (**Fig. 5E**). Notably, both anti-BCORP1 and anti-KAT2A Ab levels rose over time,

especially in mild COVID-19 group for anti-BCORP1 and in moderate to severe

COVID-19 group for anti-KAT2A (**Fig. 5F**). Additional analysis did not find any

correlation between these two autoantibodies and IgG targeting N, S, and RBD at either

timepoint or their progression over time (**Fig. 5G and 5H**).

Discussion

Herein we conducted PWAbS subjecting serum samples derived from HCs and

patients with COVID-19, AD, AAV, SLE, and SSc (**Fig. 1A**). We demonstrated that

our PWAbS methodology enables us to identify disease-specific autoantibodies (**Fig.**

2A, 2B, and 2C), which demonstrate the distinct distribution of autoantibodies and

common biological processes among different conditions (**Fig. 2D, 2E, and 2F**). The

contrast in autoantibody profiles was accentuated through the application of a machine

learning approach, particularly leveraging the XGBoost framework (**Fig. 3 and 4**). We

also investigated the longitudinal change of autoantibody profiles along with the time

course of COVID-19 and its correlation with emergence of antibodies targeting

COVID-19 particles (**Fig. 5**). Collectively, these results supported our hypothesis that

the combination of PWAbS and omics-based bioinformatic methodologies is adaptable

to human disorders including COVID-19. Additionally, our findings in this study as

well as our previous works provide a comprehensive catalog of autoantibody profiles in

various diseases and open the door to creating innovative diagnostic methods that can

differentiate between various disease mechanisms affecting multiple organs, utilizing

distinct autoantibody patterns measured by WPAs.[17,19]

The machine learning-based approach has discovered that the presence of

anti-KAT2A antibodies is highly specific to COVID-19 (**Fig. 4G and 4H**). The levels

of anti-KAT2A Abs increased over the course of COVID-19 but were not correlated to

antibodies targeting SARS-CoV-2 particles (**Fig. 5H**). This observation indicates that

autoantibodies to KAT2A emerge because of autoantigen exposure due to tissue

damage triggered by COVID-19, not as a reflection of cross-reaction between

SARS-CoV-2 virions. KAT2A functions as a histone acetyltransferase that plays a role

in the epigenetic regulation of the genome by modifying chromatin structures. There is

notable research by John K. et al., indicating that the SARS-CoV-2 ORF8 protein

mimics the histone H3's ARKS motifs, which interfere with the role of KAT2A role in

host cell epigenetic regulation.[28] Intriguingly, the results of ELISA utilizing

recombinant KAT2A produced in a Baculovirus expression system showed statistifcally

significant positive correlation with our PWAbS results (**Extended Fig. 6A**), supporting

the validity of our method for quantifying autoantibodies across different protein

synthesis systems.

Anti-BCORP1 antibodies were also found to be specifically elevated in the sera

of COVID-19 patients (**Fig. 4E and 4F**). Despite *BCORP1* being categorized as a

pseudogene, it appears to undergo transcription into mRNA, as several transcriptomic

studies have reported the presence of *BCORP1*-derived sequences.[29,30] Especially, Deng

MC's research has shown that the transcription levels of *BCORP1* in peripheral blood

mononuclear cells of COVID-19 patients correlate with early functional recovery and

1-year survival.[30] However, it remains unclear whether *BCORP1* mRNA is translated

into functional proteins, and further investigation is needed in this regard. Moreover,

our discovery of anti-BCORP1 Abs in both males and females raises questions, as

BCORP1 is located on the Y chromosome. This leads us to consider the possibility of

cross-reactivity of these antibodies against foreign antigens, such as proteins comprising

SARS-CoV-2 virions. However, we could not find any correlation between serum

levels of anti-BCORP1 Abs and antibodies targeting SARS-CoV-2 particles at any of

the timepoints examined, nor in their changes over time (**Fig. 5G**). Another hypothesis

is cross-reaction between the antigen we produced from *BCORP1* cDNA and other

human proteins. The *BCOR* gene, the counterpart of *BCORP1* found on the X

chromosome, has a nucleotide sequence that is over 99% identical to *BCORP1*. As our

cDNA library lacked BCOR cDNA, we used recombinant BCOR synthesized in

HEK293 cells to perform ELISA for anti-BCOR antibody detection. The results showed

no correlation with anti-BCORP1 antibody measurements obtained via WPA

(**Extended Fig. 6B**), suggesting two possibilities: (1) the autoantibodies in COVID-19

target a different region of BCORP1 than BCOR, or (2) the autoantibodies recognize a

shared region, but differences in their three-dimensional structures—potentially due to

the recombinant BCOR not being preserved in a hydrated state—resulted in

dissociation.

Our study has multiple strengths. First, the wheat-germ *in vitro* protein

synthesis system and technique for manipulation of WPAs realized high-throughput

expression of various human proteins including exoproteome upon a single platform.

Second, as a result, our autoantibody measurement could cover a wider range of

antigens at an almost proteome-wide level, which enabled us to apply omics-based

bioinformatical approaches for interpreting the data. Third, engagement of machine

learning methodologies enabled us to identify autoantibodies highly specific to

COVID-19. Fourth, we investigated the longitudinal change of autoantibody profiles

within COVID-19 patients, along with the measurement of antibodies targeting

SARS-CoV-2 particles.

The limitation of our present study includes its retrospective design and a

relatively small number of the subjects. The demographic differences, such as sex and

age, between COVID-19 patients and other groups, including HCs, raise concerns about

potential confounding, as previous studies have linked age and sex to autoantibody

profiles.[31–33] Additionally, it is important to note that critically ill patients were included

only in the COVID-19 group, and elevated autoantibodies have been reported in

critically ill individuals without COVID-19.[34] Furthermore, we could not distinguish

whether the autoantibodies found in our measurement were predisposed before

COVID-19 or newly appeared after infection. In addition, functional assays for the

autoantibodies such as neutralizing assays or *in vivo* studies are lacking. Therefore,

insights into the direct contribution of each autoantibody to the pathophysiology of

COVID-19 are limited. Our next challenges would include collecting serum samples

before and after COVID-19 by accessing to population-based cohorts, recruiting sex,

age, and severity-matched controls, evaluating the function of each autoantibody against

their target molecules, and testing their contribution to the pathogenesis in animal

experiments. From a machine learning aspect, there is another limitation caused by the

small amount of data and imbalanced data. The small and imbalanced data may lead our

model to fail to capture important features to discriminate against COVID-19 patients.

This concern often arises in material science and life science. Nevertheless, in material

science, it is revealed that various machine learning techniques, including XGBoost, are

effective for such data[35]. Similarly, in life science, Parkinson's disease specific features

are identified from small and imbalanced data[36]. Therefore, in this study, various

machine learning techniques we used are also considered to be effective in identifying

the specific features of COVID-19 patients. To be more persuasive, we investigate the

effectiveness of our discovered features from a clinical aspect instead of increasing the

samples. As our future work, it is important to verify the discovered features'

effectiveness using more samples.

In conclusion, our study highlights the utility of PWAbS combined with

bioinformatics-based autoantigenomics in identifying disease-specific autoantibody

signatures. The findings not only provide insights into the unique autoantibody profiles

of COVID-19 but also underscore the potential of this approach in understanding

immune dysregulation across various diseases. By leveraging machine learning, we

identified anti-BCORP1 and anti-KAT2A antibodies as highly specific markers for

COVID-19, paving the way for innovative diagnostic methods. Validation of these

findings in external cohorts will be crucial to confirm their generalizability and clinical

utility, as well as to further explore the functional roles of these autoantibodies in

disease mechanisms.

References

1.   Grp, C. S. & Version, P. The species Severe acute respiratory syndromerelated

coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.*

5, 5346–544 (2020).

2.   Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and

COVID-19. *Nat. Rev. Microbiol.* **19**, 141–154 (2021).

3.   Mehta, P. *et al.* COVID-19: consider cytokine storm syndromes and

immunosuppression. *Lancet* **295**, 1033–1034 (2020).

4.   Huang, C. *et al.* Clinical features of patients infected with 2019 novel

coronavirus in Wuhan , China. *Lancet* **395**, 497–506 (2020).

5.   Dessie, Z. G. & Zewotir, T. Mortality□related risk factors of COVID□19: a

systematic review and meta□analysis of 42 studies and 423,117 patients. *BMC*

Infect. Dis. **21**, 855 (2021).

6.   Bastard, P. *et al.* Autoantibodies against type I IFNs in patients with

life-threatening COVID-19. *Science (80-.).* **370**, (2020).

7.   Bastard, P. *et al.* Autoantibodies neutralizing type I IFNs are present in ~4% of

uninfected   individuals over 70 years old and account for ~20% of COVID-19

deaths. *Sci. Immunol.* **6**, (2021).

8.   Eto, S. *et al.* Neutralizing Type I Interferon Autoantibodies in Japanese Patients

with Severe   COVID-19. *J. Clin. Immunol.* **42**, 1360–1370 (2022).

9.   Vazquez, S. E. *et al.* Autoantibody discovery across monogenic, acquired, and

COVID-19-associated autoimmunity with scalable PhIP-seq. *Elife* **11**, e78550

(2022).

10.   Credle, J. J. *et al.* Unbiased discovery of autoantibodies associated with severe

COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries.

Nat. Biomed. Eng. **6**, 992–1003 (2022).

11.   Puel, A., Bastard, P., Bustamante, J. & Casanova, J.-L. Human autoantibodies

underlying infectious diseases. *J. Exp. Med.* **219**, e20211387 (2022).

12.   Cheng, A. & Holland, S. M. Anti-cytokine autoantibodies: mechanistic insights

and disease associations. *Nat. Rev. Immunol.* (2023)

doi:10.1038/s41577-023-00933-2.

13.   Muri, J. *et al.* Autoantibodies against chemokines post-SARS-CoV-2 infection

correlate with disease course. *Nat. Immunol.* **24**, 604–611 (2023).

14.   Wang, E. Y. *et al.* Diverse functional autoantibodies in patients with COVID-19.

Nature **595**, 283–288 (2021).

15.   Chang, S. E. *et al.* New-onset IgG autoantibodies in hospitalized patients with

416   COVID-19. *Nat. Commun.* **12**, 5417 (2021).

417   16.   Cabral-marques, O. *et al.* Autoantibodies targeting GPCRs and RAS-related

418   molecules associate with COVID-19 severity. *Nat. Commun.* **13**, 1220 (2022).

419   17.   Matsuda, K. M. *et al.* Autoantibody Landscape Revealed by Wet Protein

420   Array : Sum of Autoantibody Levels Re fl ects Disease Status. *Front. Immunol.*

421   **13**, 1–14 (2022).

422   18.   Matsuda, K. M., Kotani, H., Yamaguchi, K., Okumura, T. & Fukuda, E.

423   Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis

424   revealed by proteome-wide autoantibody screening. *J. Autoimmun.* **135**, 102995

425   (2023).

426   19.   Kuzumi, A. *et al.* Comprehensive autoantibody profiling in systemic

427   autoimmunity by a highly-sensitive multiplex protein array. *Front. Immunol.* **14**,

428   (2023).

429   20.   Goshima, N. *et al.* Human protein factory for converting the transcriptome into

430   an in vitro-expressed proteome. *Nat. Methods* **5**, 1011–1017 (2008).

21.   Sawasaki, T., Ogasawara, T., Morishita, R. & Endo, Y. A cell-free protein

synthesis system for high-throughput proteomics. *Proc. Natl. Acad. Sci. U. S. A.*

99, 14652–14657 (2002).

22.   Sawasaki, T. *et al.* A bilayer cell-free protein synthesis system for

high-throughput screening of gene products. *FEBS Lett.* **514**, 102–105 (2002).

23.   Endo, Y. & Sawasaki, T. Cell-free expression systems for eukaryotic protein

production. *Curr. Opin. Biotechnol.* **17**, 373–380 (2006).

24.   Fukuda, E. *et al.* Identification and characterization of the antigen recognized by

the germ cell mAb TRA98 using a human comprehensive wet protein array.

Genes to Cells **26**, 180–189 (2021).

25.   Moritz, C. P. *et al.* Autoantigenomics: Holistic characterization of autoantigen

repertoires for a better understanding of autoimmune diseases. *Autoimmun. Rev.*

19, 102450 (2020).

26.   Eisenberg, E. & Levanon, E. Y. Human housekeeping genes, revisited. *Trends*

Genet. **29**, 569–574 (2013).

27.   The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects

across human. *Science (80-.).* **369**, 1318–1330 (2020).

28.   Kee, J. *et al.* SARS-CoV-2 disrupts host epigenetic regulation via histone

mimicry. *Nature* **610**, 381–388 (2022).

29.   Fagerberg, L. *et al.* Analysis of the human tissue-specific expression by

genome-wide integration of transcriptomics and antibody-based proteomics. *Mol.*

Cell. Proteomics **13**, 397–406 (2014).

30.   Deng, M. C. Multi-dimensional COVID-19 short- and long-term outcome

prediction algorithm. *Expert Rev. Precis. Med. drug Dev.* **5**, 239–242 (2020).

31.   Hooper, B., Whittingham, S., Mathews, J. D., Mackay, I. R. & Curnow, D. H.

Autoimmunity in a rural community. *Clin. Exp. Immunol.* **12**, 79–87 (1972).

32.   Ioannidis, J. P. A., Katsifis, G. E., Stavropoulos, E. D., Manoussakis, M. N. &

Moutsopoulos, H. M. Evaluation of the association of autoantibodies with

mortality in the very elderly: a cohort study. *Rheumatology* **42**, 357–361 (2003).

33.   Nisihara, R. *et al.* Antinuclear Antibodies and Rheumatoid Factor Positivity in

Healthy Elderly Adults: A Cross-Sectional Study in 336 Individuals. *J. Am.*

Geriatr. Soc. **61**, 2044–2046 (2013).

34.   Trahtemberg, U. *et al.* COVID-19-associated autoimmunity as a feature of acute

respiratory failure. *Intensive Care Med.* **47**, 801–804 (2021).

35. Xu, P., Ji, X., Li, M. & Lu, W. Small data machine learning in materials science.

npj Comput. Mater. **9**, 42 (2023).

36. Zheng, L. *et al.* Contrastive machine learning reveals Parkinson's disease specific

features associated with disease severity and progression. *Commun. Biol.* **7**, 954

(2024).

37. Yamakawa, K. *et al.* Japanese rapid/living recommendations on drug

management for COVID □19: updated guidelines (July 2022). *Acute Med. Surg.*

9, 1–21 (2022).

38. WILLIAMS, H. C. *et al.* The U.K. Working Party's Diagnostic Criteria for

Atopic Dermatitis.: I. Derivation of a minimum set of discriminators for atopic

dermatitis. *Br. J. Dermatol.* **131**, 383–396 (1994).

39. Watts, R. *et al.* Development and validation of a consensus methodology for the

classification of the ANCA-associated vasculitides and polyarteritis nodosa for

epidemiological studies. *Ann. Rheum. Dis.* **66**, 222–227 (2007).

40. Aringer, M. *et al.* 2019 European League Against Rheumatism/American

College of Rheumatology Classification Criteria for Systemic Lupus

Erythematosus. *Arthritis Rheumatol.* **71**, 1400–1412 (2019).

41.   Van Den Hoogen, F. *et al.* 2013 classification criteria for systemic sclerosis: An

american college of rheumatology/European league against rheumatism

collaborative initiative. *Arthritis Rheum.* **72**, 1747–55 (2013).

42.   Nakano, Y. *et al.* Time course of the sensitivity and specificity of

anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan.

Sci. Rep. **11**, 1–10 (2021).

43.   Qian, C. *et al.* Development and multicenter performance evaluation of fully

automated SARS-CoV-2 IgM and IgG immunoassays. *Clin. Chem. Lab. Med.* **58**,

1601–1607 (2020).

44.   Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis

of systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).

Acknowledgements

We thank Ms. Maiko Enomoto and her colleagues for secretary work. We

thank Ms. Teruko Tani and Ms. Mayumi Odagiri for their assistance in clinical data

collection. We appreciate Ms. Maiko Matsuda, VESPER Studio Inc., Tokyo, Japan, for

her contribution of illustrating skills.

Author Contributions

KM Matsuda primarily engaged in autoantibody measurement, clinical data

collection, data analysis, visualization, and writing the first draft of the manuscript. Y

Kawase primarily contributed to machine learning analysis. K Iwadoh also participated

in machine learning analysis. M Kurano, Y Yatomi, K Okamoto, and K Moriya

participated in sample collection and clinical data acquisition regarding COVID-19. H

Kotani oversaw ELISA experiments. A Kuzumi, T Fukasawa, A Yoshizaki-Ogawa took

part in the sample collection of SSc. T Hisamoto was in charge of sample collection of

AD. M Kono, T Okamura, H Shoda, and K Fujio oversaw sample collection of SLE. K

Yamaguchi, T Okumura, C Ono, Y Kobayashi, A Sato, A Miya, and N Goshima

prepared wet protein arrays, provided technical assistance for autoantibody

measurement, participated in data analysis, setup of UT-ABCD, and revised the

manuscript. R Uchino, Y Murakami and H Matsunaka provided technical assistance for

autoantibody measurement. H Imai and R Raymond supervised the study. S Sato

conceptualized and supervised the study. A Yoshizaki conceptualized, launched, and

supervised this study, and was involved in revising the manuscript.

Conflict-of-interest statement

K Yamaguchi, T Okumura, C Ono, Y Kobayashi, A Miya, A Sato, and N

Goshima were employed by ProteoBridge Corporation. T Fukasawa and A Yoshizaki

belong to the Social Cooperation Program, Department of Clinical Cannabinoid

Research, The University of Tokyo Graduate School of Medicine, Tokyo, Japan,

supported by Japan Cosmetic Association and Japan Federation of Medium and Small

Enterprise Organizations. T Okamura belongs to the Social Cooperation Program,

Department of Functional Genomics and Immunological Diseases, The University of

Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Chugai

Pharmaceutical Corporation. The remaining authors declare that the research was

conducted in the absence of any commercial or financial relationships that could be

construed as a potential conflict of interest.

Data availability statement

The digest of the results is available as "aUToAntiBody Comprehensive

Database (UT-ABCD)" at http://www.ut-abcd.org. The full dataset is available upon

reasonable request to the corresponding author, in compliance with ethical guidelines

and participant privacy considerations.

Materials and Methods

Human subjects

We consecutively enrolled patients administered to our institution for COVID-19 from April 2020 to April 2021. Inclusion criteria were a SARS-CoV-2 positive nasopharyngeal swab test by real-time reverse transcription-polymerase chain reaction (RT-PCR) and age ≥18 years. A Ct value of 38 cycles was used as the threshold for determining a positive result in RT-PCR. Clinical data were collected by retrospective review of electric medical records. We gathered basic patient information, symptoms, medications, histopathologic features, and laboratory findings from the closest time point from the date of serum collection. The disease severity was assessed following the Japanese guideline for managing COVID-19 patients.[37] In brief, individuals requiring intensive care or mechanical ventilation were categorized as severe COVID-19, those exhibiting hypoxemia among the remaining cases were classified as moderate to severe COVID-19, and all other patients were considered to have mild COVID-19. Data were derived from samples collected at an "early" time point, defined as within 10 days of symptom onset. Additionally, for Figure 5, we included samples from the same COVID-19 patients collected at a "late" time point (11–20 days after symptom onset) in 41 patients, where available. We also gathered

serum samples from HCs and patients with AD, AAV, SLE, and SSc. HCs were

randomly recruited from healthcare providers with no medical history, who underwent

annual health checkups. Patients with AD, AAV, SLE, and SSc were recruited from

individuals regularly visiting The University of Tokyo Hospital, all of whom met the

diagnostic or classification criteria for their respective conditions.[38-41] This study has

been approved by The University of Tokyo Ethical Committee (Approval number 0695).

Written informed consent has been obtained from all the participants.

Measurement of IgG targeting SARS-CoV-2 particles

The process of quantifying IgG antibodies that target specific SARS-CoV-2

proteins, namely the nucleocapsid protein, spike protein, and the spike protein's

receptor binding domain, was conducted as outlined previously using a commercial

SARS-CoV-2 IgG kit (YHLO Biotechnology Company, Ltd., Shenzhen, China).[42,43]

This involved an assay where serum samples were combined with magnetic beads

coated with the viral proteins and a substance to prepare the samples. This mix was then

washed, combined with an acridinium-conjugated anti-human IgG, and washed again.

The subsequent steps included adding solutions to induce a chemiluminescent reaction,

the intensity of which was measured by the iFlash3000 CLIA analyzer (YHLO

Biotechnology Company, Ltd.) A threshold of 10 AU/mL was used for the detection,

following the guidelines provided by the manufacturer.

Autoantibody measurement

WPAs were arranged as previously described.[17] First, proteins were

synthesized *in vitro* utilizing a wheat germ cell-free system from 13,352 clones of the

HuPEX.[20] POLR3A and TRIM21 existed in two forms: full-length and truncated. All

other proteins were full-length. Second, synthesized proteins were plotted onto glass

plates (Matsunami Glass, Osaka, Japan) in an array format by the affinity between the

GST-tag added to the N-terminus of each protein and glutathione modified on the

plates. All autoantigens were presented in duplicate on the WPAs. The array also

included mock spots as negative controls (wheat germ cell-free protein synthesis

products without any cDNA) and IgG spots as positive controls (wheat germ cell-free

protein synthesis products with IgG-coding cDNA). The WPAs were treated with

human serum diluted by 1:333 in the reaction buffer containing 1x Synthetic block

(Invitrogen), phosphate-buffered saline (PBS), and 0.1% Tween 20. Next, the WPAs

were washed, and goat anti-Human IgG (H+L) Alexa Flour 647 conjugate (Thermo

Fisher Scientific, San Jose, CA, USA) diluted 1000-fold was added to the WPAs and

reacted for 1 hour at room temperature. Finally, the WPAs were washed, air-dried, and

fluorescent images were acquired using a Typhoon imaging system (Cytiva,

Marlborough, MA, USA). Fluorescence images were analyzed to quantify serum levels

of autoantibodies targeting each antigen, following the formula shown below:

$$Autoantibody\ level\ [AU] = \frac{F_{auto\,antigen} - F_{negative\ control}}{F_{positive\ control} - F_{negative\ control}} \times 100$$

AU: arbitrary unit

$F_{autoantigen}$: fluorescent intensity of autoantigen spot

$F_{negative\ control}$: fluorescent intensity of negative control spot

$F_{positive\ control}$: fluorescent intensity of positive control spot

When there was a significant discrepancy between the results of duplicate spots,

we examined the raw fluorescence images and excluded abnormal signals, such as noise

generated by dust particles. SAL was defined as the sum of serum levels for all 13,352

autoantibodies tested in our study.

Machine learning

We trained supervised machine learning models for classification tasks using

simple linear regression, Ridge regression, logistic regression with normalization,

logistic regression with standardization, SVM with normalization, SVM with

standardization, and XGBoost. These models were implemented using the scikit-learn

library (https://scikit-learn.org/) in Python (v.3.11.11) and trained within a Jupyter

Notebook environment. Hyperparameter tuning was conducted using Optuna

(https://optuna.org/).

For simple linear regression, Ridge regression, and logistic regression, we used

the "sklearn.linear_model" module. For Ridge regression, the hyperparameter "alpha"

was searched between 0.0001 and 10.0 on a logarithmic scale, and the optimal value

was determined to be 9.994. For logistic regression, we performed standardization or

normalization of the data using the "sklearn.preprocessing" module.

For SVM, implemented using the "sklearn.svm" module, we applied

standardization or normalization with the "sklearn_preprocessing" module, and feature

importance was assessed by averaging the number of splits each feature contributed to

over cross-validation.

For XGBoost, we used the "xgboost" module and performed hyperparameter

tuning over the following ranges: "n_estimators" (100–1000), "max_depth" (3–9),

"learning_rate" (1e-3–1e-1) on a logarithmic scale, "subsample" (0.6–1.0),

"colsample_bytree" (0.6–1.0), "min_child_weight" (1–10), "reg_lambda" (1e-8–10.0)

on a logarithmic scale, and "reg_alpha" (1e-8–10.0) on a logarithmic scale. The best

hyperparameters obtained were "n_estimators": 556, "max_depth": 4, "learning_rate":

0.003, "subsample": 0.939, "colsample_bytree": 0.635, "min_child_weight": 8,

"reg_lambda": 0.370, and "reg_alpha": 2.210.

Performance Metrics

We performed the 10-fold cross-validation as follows: first, we shuffled and

split the data into 10 equally sized parts, selecting one of these parts as validation data

while the remaining 9 parts as training data. We then repeated this procedure 10 times,

selecting a different part as the validation data. Model performance on the testing set

was evaluated using the following metrics:

- Accuracy: $\frac{TP+TN}{TP+FP+TN+FN}$

- Precision: $\frac{TP}{TP+FP}$

- Recall: $\frac{TP}{TP+FN}$

- F1-score: $\frac{2 \times TP}{2 \times TP+FP+FN}$

- Matthew's Correlation Coefficient (MCC): $\frac{TP \times TN - FP \times FN}{\sqrt{(TP+FP)(TP+FN)(TN+FP)(TN+FN)}}$

TP: true positive

FP: false positive

645    TN: true negative

646    FN: false negative

648  *Feature importance scores and feature selection*

649    The feature importance was indicated by their mean absolute coefficient in the

650  10-fold cross validation in simple linear regression, Ridge regression, and logistic

651  regression. As for SVM and XGBoost, the feature importance was represented by

652  F-scores, meaning the average number of splits by each feature over the cross-validation.

653  When constructing minimum feature models, we selected only the top 1–5 features

654  ranked by F-scores for final model training in each cross-validation iteration. In all

655  other cases, we analyzed either all measured autoantibodies alone or in combination

656  with age and sex.

658  *Enzyme-Linked Immunosorbent Assay*

659    Two 96-well antigen-binding plates were prepared: one for antigen coating and

660  another for negative control. Each well was initially filled with 50 µL of

661  phosphate-buffered saline (PBS). After incubation for 5 minutes at room temperature

662  (RT), the liquid was removed. A solution of recombinant KAT2A (MyBioSource, San

Diego, CA, USA) or recombinant BCOR (OriGene Technologies, Rockville, MD,

USA) was prepared at a concentration of 3 µg/mL in PBS. Subsequently, 30 µL of the

antigen solution was added to each well of the antigen coating plate, while 30 µL of

PBS alone was added to the wells of the negative control plate. The plates were then

incubated at 300 rpm for 1.5 hours at RT to facilitate antigen binding. After incubation,

the plates were washed three times with 120 µL of PBST (PBS containing 0.1%

Tween-20) per well. Blocking was performed by adding 100 µL of blocking buffer

(0.5% skim milk in PBST) to each well. The plates were sealed with transparent

adhesive film and incubated at 300 rpm for 1 hour at RT. Following blocking, adjusted

serum reaction solutions were prepared and pipetted into the plates, with 50 µL added to

each well. The plates were sealed with aluminum adhesive film and incubated at 860

rpm for 1 hour at RT. The plates were washed three times with 120 µL of TBST

(Tris-buffered saline containing 0.1% Tween-20). Subsequently, 50 µL of secondary

antibody solution, goat anti-Human IgG (H+L) Alexa Flour 647 conjugate (Thermo

Fisher Scientific) diluted 1:1000 in TBST, was added to each well. The plates were

again sealed and incubated for 1 hour at RT. After the secondary antibody reaction, the

plates were washed three times with 120 µL of TBST. Then, 50 µL of TBST was added

to each well. Fluorescence signals were scanned using a Typhoon imaging system

(Cytiva). The serum autoantibody levels were quantified by calculating the difference in

fluorescent signals between the antigen-coated plate and the negative control plate.

Statistical analysis

Two-group comparisons were performed using two-sided Fisher's exact test for

categorical variables and two-sided Mann-Whitney U test for continuous variables.

P-value of < 0.05 was considered statistically significant. Differentially elevated

autoantibodies were defined as more than 2-fold changes in the serum levels with a

false discovery rate (FDR) < 0.05, adjusted using the Benjamini-Hochberg method.

Gene Ontology Analysis using web-based tools targeted the list of the entry clones

coding the differentially highlighted autoantigens was performed for gene-list

enrichment analysis, gene-disease association analysis, and transcriptional regulatory

network analysis with Metascape.[44] As a reference, we utilized the list of all the genes

included in our cDNA library used for WPA manipulation. Other data analyses and

presentations were conducted using Stata IC/15.0 (StataCorp, TX, USA).

Data visualization

Box plots, scatter plots, hierarchical clustering and correlation matrix were

visualized by using R (v4.2.1). Box plots were defined as follows: the middle line

corresponds to the median; the lower and upper hinges correspond to the first and third

quartiles; the upper whisker extends from the hinge to the largest value no further than

1.5 times the interquartile range (IQR) from the hinge; and the lower whisker extends

from the hinge to the smallest value at most 1.5 times the IQR of the hinge.

Data availability

706   The digest of the results is accessible at http://www.ut-abcd.org. The full

707   dataset is available upon reasonable request to the corresponding author, in compliance

708   with ethical guidelines and participant privacy considerations.

709   **Code availability**

710   All the scripts are available at https://github.com/mkazukikom/COV19ML.

Figure legends

Figure 1. Overview of PWAbS methodology.

(A) Scheme of PWAbS pipeline. In the first step, proteins were synthesized *in vitro* from the proteome-wide human cDNA library (HuPEX). Promotors (P), Enhancers (E), and FLAG-GST tags were fused to open reading frames of the expression clones by Gateway LR reaction. After polymerase chain reaction amplification and *in vitro* transcription, translation was performed using the wheat germ cell-free synthesis system. In the second step, we prepared WPAs by plotting synthesized proteins onto glass slides in an array format. WPAs were treated with serum samples derived from diseased patients or HCs. Autoantibodies were detected by fluorochrome-conjugated anti-human IgG Ab. In the third step, autoantibody quantification was performed based on the fluorescent values. Analysis of acquired high-dimensional autoantibody profiles was conducted by multiple omics-based approaches. ORF: open reading frame. (B) A venn diagram shows our WPA covers 84.8% of human housekeeping genes. (C) A venn diagram illustrates our WPA covers 72.1% of expressed human genes, based on genes expressed at more than 3.5 TPM in the GTEx V8, a bulk RNA-seq data from 52 human tissues and two cell lines.

Figure 2. Identification of disease-specific autoantibodies.

(A) Box plots that show the count of autoantibody positivity in each individual by different condition. ***: P < 0.001. P-values were calculated by two-sided Mann Whitney U test compared to HCs. (B) Volcano plots that illustrate differentially elevated autoantibodies within each condition compared to HCs. Red horizontal dash lines indicate false discovery rate (FDR) = 0.05. FDR was calculated by two-sided Mann Whitney U test with Benjamini-Hochberg correction compared to HCs. Red vertical dash lines indicate Log2 Fold Change (Disease/HC) = ±1. (C) Venn diagram that demonstrates the subsumptions among disease-specific autoantibodies. (D) UMAP plot that illustrates the distribution of disease-specific autoantibody profiles of each individual. (E) Heat map that shows the result of enrichment analysis targeting the genes responsible for the proteins targeted by such disease-specific autoantibodies. P values were calculated utilizing the list of 13,550 genes included in our cDNA library used for WPA manipulation as a reference. (F) Circos plot that depicts the overlap of the gene lists responsible for the proteins targeted by the disease-specific autoantibodies at the biological function level.

Figure 3. Autoantibodies highlighted in each machine learning model.
Autoantibodies that are mostly highlighted according to feature importance in two-class
(A), three-class **(B)**, and multi-class **(C)** classifications. The feature importance is
represented by F-scores, meaning the average number of splits by each feature over the
cross-validation. Correlograms depict correlations, showcasing the connection between
the highest-ranked autoantibodies in two-class **(D)**, three-class **(E)**, and multi-class **(F)**
classifications. The correlation strength is denoted by Spearman's rho on the color scale.
Circle sizes represent the significance of the p-values, with only those with $P < 0.05$
being displayed. Radar charts present the average normalized quantities of the most
important autoantibodies in each model, with line colors distinguishing between
different disease categories in two-class **(G)**, three-class **(H)**, and multi-class **(I)**
classifications.

Figure 4. COVID-19 signature of autoantibody landscape. (A) The heatmap's columns display the serum autoantibody concentrations highlighted in the multi-class classification using XGBoost. **(B)** PCA graph plots individual participants as points, with color coding to differentiate among various disease classes. **(C)** The loading diagram illustrates the contributions to PC1 and PC2, with I, II, and III marking the clusters defined in (A). **(D)** The bar graphs show the loadings of each autoantibody on PC1 and PC2. **(E)** A box plot presents the serum levels of anti-BCORP1 Abs in the subjects. **: $P < 0.01$, ***: $P < 0.001$. P-values were calculated by two-sided Mann Whitney U test compared to HCs. The red horizontal dash line indicates mean + 4SD in HCs. **(F)** A ROC curve illustrates the sensitivity and specificity for COVID-19 identification by serum levels of anti-BCORP1 Abs. The red dot marks the cutoff value set at mean + 4SD in HCs. **(F)** A box plot indicates the serum levels of anti-KAT2A Abs in the subjects. ns: $P > 0.05$, **: $P < 0.01$, ***: $P < 0.001$. P-values were calculated by two-sided Mann Whitney U test compared to HCs. The red horizontal dash line indicates mean + 4SD in HCs. **(G)** A ROC curve illustrates the sensitivity and specificity for COVID-19 identification by serum levels of anti-KAT2A Abs. The red dot marks the cutoff value set at mean + 4SD in HCs.

Figure 5. Longitudinal change of humoral immune response in COVID-19. (A) This box plot outlines the serum concentrations of IgG antibodies against N, S, or RBD in patients with COVID-19 at two intervals: "early" signifies within 10 days of symptom onset, and "late" refers to 11-20 days after symptoms appear. A red dashed line marks the threshold for a positive test result. ***: $P < 0.001$. P-values were calculated by two-sided Wilcoxon singed rank test. **(B)** These box plots demonstrate the SAL in patients with COVID-19 during the "early" and "late" time points. ns: $P > 0.05$. P-values were calculated by two-sided Wilcoxon singed rank test. **(C)** The volcano plot highlights biomarkers that are significantly increased (in red) or decreased (in blue) over time in patients with COVID-19. **(D)** A Venn diagram illustrates the overlap between autoantibodies that changed over time and those specific to COVID-19. **(E)** The correlogram visualizes the relationships between the overlapping autoantibodies that either increased over time or are specific to COVID-19, with the color scale indicating the strength of correlation according to Spearman's rho and circle sizes depicting the significance of p-values, focusing on those with $P < 0.05$. **(F)** These box plots depict the time-based evolution of serum levels of anti-BCORP1 and anti-KAT2A antibodies in COVID-19 patients, categorized by disease severity. ns: $P > 0.05$, *: $P < 0.05$, **: $P < 0.01$. P-values were calculated by two-sided Wilcoxon singed rank test.

(G)(H) The scatter plots illustrate the correlation between serum levels of anti-BCORP

or anti-KAT2A Abs and IgG antibodies against the COVID-19 components at different

time points, as well as their progression over time. The red lines and the surrounding

shaded areas indicate the regression line and the 95% confidence interval, respectively.

Extended Figure 1. The sum of autoantibody levels by sex and age. (A) A box plot illustrates sum of autoantibody levels (SAL) in each individual by different condition. SAL was defined as the sum of serum levels for all 13,352 autoantibodies tested in our study. ns: $P > 0.05$, ***: $P < 0.001$. P-values were calculated by two-sided Mann Whitney U test compared to HCs. **(B)** Box plots show SAL by sex and age groups. P-values were calculated by two-sided Mann Whitney U test compared to HCs. **(C)** A jitter plot displays the distribution of Z-scores for each measured autoantibody in healthy controls (HCs), arranged in descending order of their maximum Z-score values. The red horizontal dashed line marks Z-score = 4. **(D)** A histogram illustrates the distribution of Z-scores for all autoantibody measurements in HCs, with a red vertical dashed line marking Z-score = 4. **(E)** A cumulative histogram illustrates the distribution of Z-scores for all autoantibody measurements in HCs, with a red vertical dashed line marking Z-score = 4 and a red horizontal dashed line indicating 99%.

Extended Figure 2. Autoantibodies to cytokines or their receptors. (A) The heatmap's columns display the serum autoantibody concentrations targeting cytokines in each subject evaluated by our proteome-wide autoantibody screening. **(B)** The heatmap's columns display the serum autoantibody concentrations targeting cytokine receptors in each subject evaluated by our proteome-wide autoantibody screening. **(C)** A box plot presents the serum levels of anti-interferon alpha 2 (IFNA2) Abs in the subjects. **(D)** Another box plot indicates the serum levels of anti-interferon alpha 4 (IFN4A) Abs in the subjects.

Extended Figure 3. Feature importance of top highlighted autoantibodies in other candidate machine learning frameworks for 2-class classification. **(A)** Simple linear regression. **(B)** Ridge regression. **(C)** Logistic regression with normalization. **(D)** Logistic regression with standardization. **(E)** SVM with normalization, and **(F)** SVM with standardization. For simple linear regression, Ridge regression, and logistic regression, the feature importance was indicated by their mean absolute coefficient in the 10-fold cross validation. For SVM, the feature importance is represented by F-scores, meaning the average number of splits by each feature over the 10-fold cross-validation.

Extended Figure 4. Integration of ciilical features. Autoantibodies and clinical features that are mostly highlighted according to feature importance in two-class **(A)**, three-class **(B)**, and multi-class **(C)** classifications by XGBoost. The feature importance is represented by F-scores, meaning the average number of splits by each feature over the cross-validation.

Extended Figure 5. Performance of minimal feature models based on XGBoost using the top 1–5 features. The top-ranked 1–5 features identified by XGBoost, or all the measured autoantibodies, were utilized for a 2-class classification task to discriminate COVID-19 cases.

Extended Figure 6. Serum levels of anti-BCORP1 and anti-KAT2A Abs by sex and age. (A) A scatter plot depicts the correlation between serum levels of anti-KAT2A autoantibodies measured by wet protein arrays (WPAs) and enzyme-linked immunosorbent assays (ELISA). The red line represents the regression line, while the gray shaded area denotes the 95% confidence interval. AU: arbitrary unit. **(B)** A scatter plot depicts the correlation between serum levels of anti-BCORP1 autoantibodies measured by WPAs and serum levels of anti-BCOR autoantibodies by ELISA. The red line represents the regression line, while the gray shaded area denotes the 95% confidence interval. AU: arbitrary unit. **(C)** Serum levels of anti-BCORP1 Abs by sex and age groups. ns: P > 0.05, *: P < 0.05, **: P < 0.01, ***: P < 0.001. P-values were calculated by two-sided Mann Whitney U test compared to HCs. Red vertical dash lines indicate mean + 4SD in HC. **(D)** Serum levels of anti-KAT2A Abs by sex and age groups. ns: P > 0.05, *: P < 0.05, **: P < 0.01, ***: P < 0.001. P-values were calculated by two-sided Mann Whitney U test compared to HCs. Red vertical dash lines indicate mean + 4SD in HC.

Matsuda KM et al.

Figure 1

Matsuda KM et al.
Figure 2

Matsuda KM et al.
Figure 3

Matsuda KM et al.

Figure 4

Matsuda KM et al.

Figure 5